Understanding why children with Hutchinson-Gilford Progeria Syndrome invariably die of cardiovascular disease — and doing so at the cellular resolution — may unlock fundamental insights about how normal arterial aging proceeds across decades in healthy adults. Progeria compresses a lifetime of vascular decline into roughly 14 years, making it a rare and powerful lens onto mechanisms that may quietly operate in all aging vasculature.
Using single-cell RNA sequencing (scRNA-seq) via the high-sensitivity Smart-seq2 platform, investigators profiled aortic arch tissue from LmnaG609G/G609G mice — which carry the murine equivalent of the most common LMNA mutation underlying progeria — at multiple age points, allowing them to track transcriptional changes as disease progressed without confounding from diet-induced atherosclerosis. The data revealed that vascular smooth muscle cells (VSMCs) do not fail uniformly; instead, distinct transcriptional subpopulations emerge at different disease stages. Early-stage disease-enriched VSMCs are characterized by elevated endoplasmic reticulum stress, which later gives way to a transient compensatory proliferation surge, ultimately followed by increased apoptotic loss. Notably, somatic mutation accumulation was also detected across cell types as a feature of progerin-driven degeneration.
This work is notable for several reasons beyond the rare disease context. First, it provides one of the most granular cell-type-specific chronologies of arterial wall deterioration yet produced, offering a temporal blueprint that may help interpret normal vascular aging. Second, the identification of ER stress as an early sentinel — preceding structural remodeling — suggests a potential upstream intervention window. Third, somatic mutation burden in non-dividing arterial cells is an underappreciated aspect of cardiovascular aging that this dataset now documents with molecular specificity. Key limitations include the murine model setting and the absence of atheroprone stimuli, which means extrapolation to human disease environments requires caution. As a mechanistic atlas rather than a therapeutic trial, this is incremental but potentially high-value foundational science for the aging vascular field.
